amd: Twelve years neovascular AMD survival data

In eyedata: Open Source Ophthalmic Data Sets Curated for R

Description

To explore potential utility of survival analysis techniques for retrospective clinical practice visual outcomes in a retrospective cohort study with 12-year observation period.

Usage

data("amd")

Format

A data frame (tibble) with 6696 rows and 23 variables:

patID

anonymised patient number

sex

gender of patient (m = male, f = female)

age

age at initiation of anti-VEGF therapy (50-59 years, 60-69 years, 70-79 years, 80 years and above)

avdays_induc

arithmetical average of interval between injections in induction phase in days

ethnicity

ethnicity of patient: asian (South East Asian), caucasian Afro Caribbean, Mixed, unknown_other)

loaded

induction phase was appropriately completed within 90 days (TRUE) or not (FALSE)

time

days following initiation of anti-VEGF therapy

injgiven

whether injection was given at appointment time or not (TRUE = injections given , FALSE = injection not given)

va

visual acuity at time point in early treatment diabetic retinopathy study letter score

regimen

anti-VEGF drug given is ranibizumab only or aflibercept only

pre2013

anti-VEGF therapy initiated before October 2013 (TRUE) or after (FALSE) i.e. before or after the introduction of aflibercept, respectively

Study setting and design

Of 10,744 eyes with neovascular AMD receiving anti-VEGF therapy between October 2008 and February 2020, 7802 eyes met study criteria (treatment-naïve, first-treated eyes starting anti-VEGF therapy). Institution: Moorfields Eye Clinic, London, UK Approval was granted by the Institutional Review Board of the hospital (ROAD17/031). The study complied with the Declaration of Helsinki

Data source

All clinical information at Moorfields Eye Hospital is recorded within an electronic medical record (EMR) application (OpenEyes Foundation, London, UK). A SQL database (SQL Server Reporting Service, Microsoft Corporation, Richmond, USA) containing all the information from the EMR is in place and regular updates are performed overnight to keep the data warehouse up-to-date. VA is reported in ETDRS letter score (and categories for ETDRS < 1). The highest value (independent of measurement method) available at each visit was chosen.

Data

Types of data: de-identified human subjects data Information governance authorised Moorfields Eye Clinic 19/07/2018. age not provided as a continuous variable as in original analysis to facilitate de-identification

Source

https://doi.org/10.5061/dryad.nvx0k6dqg

See Also

Associated publication: „Insights from survival analyses during 12 years of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration“ https://doi.org/10.1001/jamaophthalmol.2020.5044

eyedata documentation built on Dec. 9, 2020, 9:07 a.m.